Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

119 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
All-trans retinoic acid and interferon-alpha-2a in patients with metastatic or recurrent carcinoma of the uterine cervix: clinical and pharmacokinetic studies. New York Gynecologic Oncology Group.
Wadler S, Schwartz EL, Haynes H, Rameau R, Quish A, Mandeli J, Gallagher R, Hallam S, Fields A, Goldberg G, McGill F, Jennings S, Wallach RC, Runowicz CD. Wadler S, et al. Among authors: mandeli j. Cancer. 1997 Apr 15;79(8):1574-80. doi: 10.1002/(sici)1097-0142(19970415)79:8<1574::aid-cncr20>3.0.co;2-u. Cancer. 1997. PMID: 9118041 Clinical Trial.
A phase II double-blind randomized study of the simultaneous administration of recombinant human interleukin-6 and recombinant human granulocyte colony-stimulating factor following paclitaxel and carboplatin chemotherapy in patients with advanced epithelial ovarian cancer.
Hochster H, Speyer JL, Mandeli JP, Runowicz C, Wadler S, Berk G, Wallach R, Holland JF. Hochster H, et al. Among authors: mandeli jp. Gynecol Oncol. 1999 Mar;72(3):292-7. doi: 10.1006/gyno.1998.5261. Gynecol Oncol. 1999. PMID: 10053098 Free article. Clinical Trial.
PSC833: initial clinical results in refractory ovarian cancer patients.
Fields A, Hochster H, Runowicz C, Speyer J, Goldberg G, Cohen C, Dottino P, Wadler S, Berk G, Gretz H, Mandeli J, Holland J, Letvak L. Fields A, et al. Among authors: mandeli j. Curr Opin Oncol. 1998 Aug;10 Suppl 1:S21. Curr Opin Oncol. 1998. PMID: 9988540 Clinical Trial. No abstract available.
Biweekly 72-hour 9-aminocamptothecin infusion as second-line therapy for ovarian carcinoma: phase II study of the New York Gynecologic Oncology Group and the Eastern Cooperative Oncology Group.
Hochster H, Plimack ER, Runowicz CD, Speyer J, Wallach RC, Sorich J, Mandeli J, Wadler S, Wright J, Muggia FM. Hochster H, et al. Among authors: mandeli j. J Clin Oncol. 2004 Jan 1;22(1):120-6. doi: 10.1200/JCO.2004.03.016. J Clin Oncol. 2004. PMID: 14701774 Clinical Trial.
Prolonged topotecan infusion with cisplatin in the first-line treatment of ovarian cancer: an NYGOG and ECOG study.
Hochster HS, Plimack ER, Mandeli J, Wadler S, Runowicz C, Goldberg G, Speyer J, Wallach R, Muggia F; New York Gynecologic Oncology Group (and phase II consortium) and the Eastern Cooperative Oncology. Hochster HS, et al. Among authors: mandeli j. Gynecol Oncol. 2006 Feb;100(2):324-9. doi: 10.1016/j.ygyno.2005.08.059. Epub 2005 Oct 25. Gynecol Oncol. 2006. PMID: 16253316 Clinical Trial.
119 results